AXLA - Axcella Health Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.08
+0.02 (+0.40%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.06
Open5.16
Bid5.06 x 1100
Ask5.07 x 1400
Day's Range5.07 - 5.29
52 Week Range2.76 - 15.99
Volume49,613
Avg. Volume67,446
Market Cap117.418M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.43
Earnings DateAug 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.33
  • Business Wire

    Axcella to Present at J.P. Morgan Healthcare Conference

    Presentation and webcast to take place at 11:30 a.m. ET on January 16

  • Business Wire

    Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones

    Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early.

  • In first Mass. biotech IPO filing of 2020, cancer startup aims for $100M
    American City Business Journals

    In first Mass. biotech IPO filing of 2020, cancer startup aims for $100M

    A Cambridge startup is launching the local biotech industry’s first IPO of the year, just one month after raising $85 million from investors.

  • Hedge Funds Staying Clear Of Axcella Health Inc. (AXLA)
    Insider Monkey

    Hedge Funds Staying Clear Of Axcella Health Inc. (AXLA)

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

  • Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
    PR Newswire

    Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

    Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.

  • Business Wire

    Axcella Presents Data at ASH Annual Meeting

    Preclinical data for constituents of AXA4010 demonstrate multifactorial potential of EMMs on red blood cell, immune and vascular health.

  • Trade Alert: The Chairman Of Axcella Health Inc. (NASDAQ:AXLA), David Epstein, Has Just Spent US$54k Buying Shares
    Simply Wall St.

    Trade Alert: The Chairman Of Axcella Health Inc. (NASDAQ:AXLA), David Epstein, Has Just Spent US$54k Buying Shares

    Even if it's not a huge purchase, we think it was good to see that David Epstein, the Chairman of Axcella Health Inc...

  • Business Wire

    Axcella Strengthens Executive Team with Key Addition and Promotion

    Axcella Health (AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that it has appointed Laurent Chardonnet as the company’s Chief Financial Officer and that it has promoted its Vice President of Legal, Heidy King-Jones, to General Counsel. “Axcella has built an exceptionally strong management team to leverage its promising development platform and rapidly advance its broad portfolio of endogenous metabolic modulator (EMM) compositions,” said Bill Hinshaw, President and Chief Executive Officer of Axcella.

  • Business Wire

    Axcella Announces Issuance of Broad Patent Covering EMM Compositions

    Axcella Health (AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the issuance of U.S. Patent 10,471,034. This is the third EMM-related patent that Axcella has received to date, and it covers an array of EMM compositions, including AXA1125 and AXA1957, the company’s product candidates for non-alcoholic steatohepatitis (NASH). “This issuance follows our two prior patents related to specific EMM compositions and methods of treating liver dysfunction and liver disease,” said Paul F. Fehlner, J.D., Ph.D., Senior Vice President and Chief Intellectual Property Officer of Axcella.

  • Business Wire

    Axcella Health Reports Third Quarter 2019 Financial Results and Provides Company Update

    CAMBRIDGE, Mass.-- -- Completed enrollment of an ongoing non-IND clinical study of AXA1125/AXA1957 in more than 100 adult subjects with NAFLD Announced intent to conduct future studies of AXA1125/AXA1957 under IND as therapeutic candidates for NASH On track to file an IND and initiate a registrational trial of AXA1665 for OHE in 2020 Initiated a non-IND clinical study of hematology candidate AXA4010 ...

  • Business Wire

    Axcella Presents Data at The Liver Meeting™ Providing New Mechanistic Insights on Observed Multifactorial Effects of its Liver Product Candidates

    Axcella Health (AXLA), a biotechnology company pioneering the research and development of novel interventions to address dysregulated metabolism and support health, today announced that it will present new data on the company’s liver product candidates at The Liver MeetingTM, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held this week in Boston.

  • Business Wire

    Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010

    Axcella Health Inc. (AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced key milestones in the development of AXA4010, the company’s first investigational hematology product candidate. Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initiated enrollment of subjects with sickle cell disease (SCD) in a non-IND clinical study.

  • Need To Know: Axcella Health Inc. (NASDAQ:AXLA) Insiders Have Been Buying Shares
    Simply Wall St.

    Need To Know: Axcella Health Inc. (NASDAQ:AXLA) Insiders Have Been Buying Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Business Wire

    Axcella Enters into Collaboration with CYTOO to Explore Impact of Dysregulated Metabolism on Muscle Physiology

    Axcella Health (AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced a collaboration with CYTOO aimed at informing the development of new AXA Candidates by leveraging CYTOO’s MyoScreenTM muscle-on-a-plate platform. This platform is expected to enable a deeper understanding of how endogenous metabolic modulator (EMM) compositions influence cellular processes governing the maintenance of muscle mass and function. Skeletal muscle is an essential metabolic organ that is critical for whole-body glucose and protein handling.

  • Bay Area biotech unicorn suffers 5th worst Wall Street debut of year
    American City Business Journals

    Bay Area biotech unicorn suffers 5th worst Wall Street debut of year

    The San Francisco company's market cap dropped by about $700 million in its first day of trading.

  • Business Wire

    Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957

    Axcella Health Inc., (AXLA) (“Axcella or the Company”) a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced liver program progress updates regarding the development of AXA1125 and AXA1957. AXA1125 and AXA1957 are novel compositions of endogenous metabolic modulators (EMMs) designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with liver health.

  • Business Wire

    Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting

    Axcella Health Inc. (AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that the company will present two posters for two of its liver health-focused AXA candidates, AXA1665 and AXA1125 at the American Association for the Study of Liver Disease (AASLD) conference taking place November 8 - 12, 2019 in Boston, MA. The continued selection of abstracts at major international conferences represents Axcella’s progress in developing endogenous metabolic modulators (EMMs). AXA1665, Axcella’s lead AXA candidate for the treatment of hepatic encephalopathy (HE), currently in a Non-IND, IRB-Approved Clinical Study in subjects with mild-moderate hepatic insufficiency, is a novel composition of endogenous metabolic modulators designed to target multiple metabolic pathways intersecting key organ systems, including liver, muscle and gut that play key roles in liver health.

  • What Type Of Shareholder Owns Axcella Health Inc.'s (NASDAQ:AXLA)?
    Simply Wall St.

    What Type Of Shareholder Owns Axcella Health Inc.'s (NASDAQ:AXLA)?

    Every investor in Axcella Health Inc. (NASDAQ:AXLA) should be aware of the most powerful shareholder groups...

  • GlobeNewswire

    Axcella Health Reports First Quarter 2019 Financial Results and Provides Company Update

    Successfully completed initial public offering, raising $71.4 million in gross proceedsPresented data on AXA1665 and AXA1125 at two leading medical conferencesIdentified drug.

  • GlobeNewswire

    Axcella Health Announces Closing of Initial Public Offering

    CAMBRIDGE, Mass., May 13, 2019 -- Axcella Health Inc., a biotechnology company pioneering the research and development of novel multifactorial interventions to address.